Behind a WeChat for help
Release time:
2023-01-12
2022 12 25 in the afternoon of 5 , a voice for help suddenly appeared in the WeChat group of employees of the pharmaceutical company: "company colleagues, who has a surplus of acetaminophen drops for children to reduce fever, can you help me out? My child has a fever of 39 degrees and is now being treated in the hospital, the hospital said that only this medicine can reduce fever, but the hospital does not have it now. I went to the pharmacy and did not find it. I only have a look in our own internal group. Please have colleagues who have this medicine to support me. Please everyone. "
As soon as this message was sent out in the group, Wu Weisheng, general manager of the pharmaceutical company, immediately responded and asked which hospital the child was in? A WeChat group immediately emerged a lot of replies, colleagues have extended a helping hand: I have a bottle here, how to give it to you; I have at home, I live in XXX community, you hurry to come and get it; my family still has a surplus, which hospital do you live in, I send you ... reply to a lot of WeChat, all warm people's hearts, in the face of the epidemic, it shows the true feelings of fraternal help and care among the employees of pharmaceutical companies.
Since the new coronavirus epidemic prevention and control measures 20 optimization, new ten optimization and other policy adjustments, pharmaceutical companies have also been recruited one after another, as of 12 April 23 more than a dozen employees have developed fever, headache, body aches and other new crown positive symptoms, need home isolation treatment. In order to understand the physical condition of employees on the weekends of 24 and 25 , and to facilitate the arrangement of Monday's work, the pharmaceutical company asked everyone to report their physical condition in the internal group. In a short period of one hour, nearly 50 employees reported symptomatic information, including high fever 39.5 degrees, sore throat and sore whole body, and one that has turned to pneumonia, and so on. Watching so many employees get sick is really worrisome. One is worried about the health of employees, and the other is how to arrange work on Monday. Every Monday and Tuesday are the busiest days for pharmaceutical companies to receive orders and deliver drugs. Nearly half of the employees are in physical condition and Monday is destined to be an extraordinary day. On the morning of 26 , Wu Weisheng, the general manager, arrived at the company, paying attention to the situation of the employees, one, two, three ... Unexpectedly, except for a dozen or so with severe symptoms, all the other employees basically arrived at the company on time, which really moved Wu Weisheng. During this period of time, after the optimization of the epidemic prevention and control policy, the demand for drugs related to the prevention and control of the new coronavirus in various medical institutions has soared, and the business volume of pharmaceutical companies has greatly increased. The daily inflow and outflow of drugs is two or three times that of the usual. All departments and posts of the company, especially the storage department, are responsible for the acceptance, warehousing and delivery of drugs. Overtime is the norm, silent dedication. Here, I would like to praise all the cadres and employees of the pharmaceutical company! This also makes us sigh with emotion that the good performance achieved by the pharmaceutical company in 2022 was not achieved out of thin air, but was the result of the company's excellent group of party members, cadres and employees, who put work first, worked hard and created benefits.
The colleague and child who sent the voice for help used antipyretics on the same day and was discharged from the hospital two days after the medication. Now they have fully recovered. In the face of the epidemic, all the staff of the pharmaceutical company showed their determination to help each other and concentrate their efforts to overcome difficulties, creating an atmosphere of unity of mutual understanding and mutual support. (Fan Tufa)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page